Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pharma Counters India Competition Commission On ‘Market-Distorting’ Practices

Executive Summary

A note by the Competition Commission of India has put the spotlight back on certain pharma industry practices that are seen as triggering non-competitive market outcomes. Pharma has called into question certain claims of the CCI, with some experts suggesting that the regulator may have also exceeded its remit.

You may also be interested in...



Regulator Warns Of Tougher Pricing Regime In India Amid ‘Market Failure’

India’s apex pricing authority concludes some in Rx industry have not played 'fair'; 25% of products show market failure, Bhupendra Singh says.

OPPI Chief Vaidheesh On Burning Industry Issues In India

The Organization of Pharmaceutical Producers of India (OPPI) essentially reflects the views of foreign firms in the country. In an interview with Scrip, OPPI’s new chief and GSK vice president (South Asia) and managing director (India) Annaswamy Vaidheesh shares the industry body’s take on several critical issues including the Indian government’s push for generic medicines and why the effective contract manufacturing model should not be “disrupted” by proposed policy reform.

Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA

Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB001859

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel